Oliver Lagore Vanvalin Investment Group Avidity Biosciences, Inc. Transaction History
Oliver Lagore Vanvalin Investment Group
- $359 Million
- Q3 2024
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 1,754 shares of RNA stock, worth $53,497. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,754
Previous 1,421
23.43%
Holding current value
$53,497
Previous $58,000
37.93%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$324 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$281 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$263 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$248 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$214 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.59B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...